Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage biotech company advancing tumor-agnostic therapies targeting oncogenic mutations in cancers like NSCLC and glioblastoma. This page provides investors and researchers with essential updates on the company’s precision oncology developments.
Find consolidated access to press releases, clinical trial data, and regulatory milestones for BDTX’s pipeline, including MasterKey therapies BDTX-1535 (EGFR inhibitor) and BDTX-4933. Track progress on mutation-targeted approaches addressing resistance mechanisms like the C797S mutation in EGFR.
Our news collection serves as a reliable resource for monitoring strategic partnerships, research publications, and FDA communications related to the company’s Mutation-Allostery-Pharmacology platform. Content is curated to help stakeholders assess scientific progress without promotional bias.
Bookmark this page for streamlined updates on Black Diamond’s efforts to expand treatment options in precision oncology. Check regularly for new developments in small-molecule kinase inhibitors and tumor-agnostic therapeutic strategies.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its President and CEO, David M. Epstein, Ph.D., will present an overview of the company's MasterKey programs, including BDTX-1535 and BDTX-4933, during the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 11:00 a.m. ET. The presentation will take place virtually, and a live webcast can be accessed on the company's investor relations website. Following the event, a replay will be available for 90 days.
Black Diamond is a clinical-stage precision oncology medicine company, focused on developing MasterKey therapies that target oncogenic mutations in genetically defined cancers. Their lead programs include BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma multiforme, and BDTX-4933 targeting RAF mutations in solid tumors. The company uses its proprietary MAP drug discovery engine to analyze genetic data and validate MasterKey mutations.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced the ongoing Phase 1 dose escalation study of BDTX-1535 targeting non-small cell lung cancer (NSCLC) with EGFR mutations and recurrent glioblastoma multiforme (GBM). Additionally, preclinical data for BDTX-4933 shows it effectively inhibits aberrant RAF signaling in models with BRAF and RAS mutations. The company presented findings at the 2023 AACR Annual Meeting, highlighting its MasterKey approach to oncology, which aims to address unmet needs in cancer treatment.
The Phase 1 study of BDTX-1535, initiated in 2022, is set to expand cohorts in 2023, while a Phase 1 trial for BDTX-4933 is scheduled for Q2 2023. The upcoming clinical updates are anticipated in the second half of this year.
Black Diamond Therapeutics (BDTX) reported its 2022 financial results, showing significant developments in its MasterKey pipeline. The company received FDA clearance for BDTX-4933 and is on track to provide a clinical update on BDTX-1535 in the second half of 2023. As of December 31, 2022, BDTX had $122.8 million in cash, enough to fund operations through Q3 2024. The company plans to initiate a Phase 1 clinical trial for BDTX-4933 in early 2023. R&D expenses decreased to $64.4 million, while net loss for 2022 was $91.2 million, improved from $125.6 million in 2021, indicating potential operational efficiencies.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present an update on the company’s advancements at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 12:50 p.m. ET in Boston, MA. The presentation will be accessible via a live webcast on the company’s investor relations page, with a replay available for 90 days post-event.
Black Diamond specializes in precision oncology, focusing on MasterKey therapies targeting oncogenic driver mutations in genetically-defined cancers, including its lead programs BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma, and BDTX-4933 targeting RAF mutations.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) will present an update on its progress at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:00 a.m. PT in San Francisco. CEO David M. Epstein will lead the presentation, focusing on the company’s advancements in precision oncology therapies targeting oncogenic driver mutations in genetically defined cancers. Black Diamond's pipeline includes clinical-stage programs BDTX-1535 and BDTX-4933, aiming to address significant unmet medical needs.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
